REVIEW Baricitinib is a selective JAK1 and JAK2 inhibitor. IC50 values are 5.9nm for JAK1, and 5.7nM for JAK2. In cell based assays Baricitinib/INCB-28050 demonstrated inhibition of intracellular signaling of multiple pro-inflammatory cytokines including IL-6 and IL-23 at concentrations of < 50 nM, and also showed good efficacy in a number of animal models at doses of 10mg/kg and below. Baricitinib is in Phase III development as a potential treatment for rheumatoid arthritis. It is in Phase II development as a potential treatment for psoriasis and diabetic nephropathy. (https://investor.lilly.com/releasedetail.cfm?releaseid=771109)
All products are stocked and shipped from the SF Bay, California, USA via FedEx, UPS or DHL.
All batches backed with full quality assurance.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
Add to Favorites 
Delete from Favorites 
